Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2004
This article has no abstract
Epistemonikos ID: cee2e0eeae84f99060b17e199975162e7b8a1885
First added on: Jan 21, 2025